Toronto Stock Exchange Symbol: MS
EDMONTON, Oct. 15 /CNW/ - BioMS Medical Corp. (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), today announced that
interim safety observations from MAESTRO-01, the Company's on-going phase III
trial of MBP8298 for the treatment of secondary progressive MS, were reported
in a poster presentation at the 23rd Congress of the European Committee for
Treatment and Research in Multiple Sclerosis (ECTRIMS) in Prague, Czech
Republic. A second poster presentation reported the percentage of patients
screened for the trial that had the target HLA-DR2/DR4 immune response genes.
ECTRIMS is one of the largest and most prestigious annual MS conferences,
bringing together MS experts and thought leaders from around the world to
discuss the latest MS research findings.
The first poster, entitled "Safety observations from administration of
MBP8298 as part of the ongoing phase III MAESTRO-01 secondary progressive MS
clinical trial", showed that MBP8298 administration resulted in no significant
safety concerns measured over the current course of the MAESTRO-01 study.
The second poster, entitled "Haplotype analysis of Secondary Progressive
Patients participating in the MAESTRO-01 Study", showed that overall, amongst
the 10 countries enrolling patients in the MAESTRO-01 trial, (Canada, United
Kingdom, Finland, Denmark, Sweden, Estonia, Latvia, Spain, Germany and the
Netherlands) 70.38% of the 788 screened patients were observed to have HLA-DR2
and/or HLA-DR4 immune response genes.
"The first poster presentation demonstrates that the safety profile of
our drug continues to look strong in a large multinational clinical trial
setting," said Kevin Giese, President and CEO of BioMS. "The second poster
reaffirms that MS patients with HLA-DR2/DR4 immune response genes, potentially
account for more than 70% of the overall MS population in Europe and Canada."
About MBP8298 - Novel Mechanism of Action
In MS patients, the body's immune system inappropriately attacks the
myelin coating around the nerves in the brain and spinal column, whereas
healthy people are "tolerant" of such normal body components. The proposed
mechanism of action of MBP8298 is, by design, to re-introduce such a state of
"tolerance" to a critical portion of the nerve's Myelin Basic Protein that is
an immunological site of attack in many MS patients. This is accomplished by
the I.V. injection of MBP8298 every six months.
Phase II and long-term follow-up treatment of MS patients with MBP8298,
recently published in the European Journal of Neurology showed that MBP8298
safely delayed the median time to disease progression for five years in
progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes.
MBP8298 is being developed in three late-stage clinical trials:
- MAESTRO-01: A pivotal phase III trial in Canada and Western Europe
evaluating MBP8298 for the treatment of secondary progressive
multiple sclerosis (SPMS). The trial is a randomized, double-blind
study and is fully recruited with 611 patients.
- MAESTRO-03: A pivotal phase III U.S. trial evaluating MBP8298 for the
treatment of SPMS. The trial is a randomized, double-blind study
enrolling approximately 510 patients.
- MINDSET-01: A phase II trial evaluating MBP8298 for the treatment of
relapsing remitting multiple sclerosis (RRMS). The trial is a
randomized, double-blind study and is fully recruited with
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and
commercialization of novel therapeutic technologies. BioMS Medical's lead
technology, MBP8298, is for the treatment of multiple sclerosis and is being
evaluated in two pivotal phase III clinical trials for secondary progressive
MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United
States. It additionally is being evaluated for relapsing remitting MS patients
in a Phase II trial in Europe entitled MINDSET-01. For further information
please visit our website at www.biomsmedical.com.
This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that MBP8298 will continue to demonstrate a satisfactory safety
profile in ongoing and future clinical trials; and that BioMS Medical Corp.
will complete the respective clinical trials within the timelines communicated
in this release. We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.
For further information:
For further information: Tony Hesby, Ryan Giese, Corporate
Communications, BioMS Medical Corp., (780) 413-7152, (780) 408-3040 Fax,
E-mail: email@example.com, Internet: www.biomsmedical.com; James Smith,
Investor Relations, (416) 815-0700 ext. 229, (416) 815-0080 Fax, E-mail: